{
    "nctId": "NCT00434031",
    "briefTitle": "CETRA: Neoadjuvant Caelyx and Trastuzumab in Her-2 Positive Breast Cancer",
    "officialTitle": "Neoadjuvant Therapy With Trastuzumab and Docetaxel Followed by Trastuzumab, Caelyx (Liposomal Doxorubicin) and Cyclophosphamide in Operable or Locally Advanced Her-2 Positive Breast Cancer",
    "overallStatus": "WITHDRAWN",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 0,
    "primaryOutcomeMeasure": "complete pathologic response rate",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histological diagnosis of breast cancer\n* Stage II-IIIB (T0-1-2-3-4-N+-M0 or T2-3-4-N0-M0; according to TNM AJCC classification, 2002)\n* Hyperexpression of HER-2/neu (HercepTest 3+ or positive FISH test)\n* Age\\> 18 e \\< 65 years\n* Left ventricular ejection fraction (LVEF) \\> or = 55%\n* ECOG Performance Status 0-2\n* Neutrophils \\> or = 2000/mm\u00b3, platelets \\> or = 100.000/mm\u00b3 , hemoglobin \\> or = 10 g/dl), GOT, GPT and bilirubin \\< 1.25 x the upper normal limit, creatinine \\< 1.25 x the upper normal limit.\n* Life expectancy \\> 3 months\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Any prior treatment for breast cancer\n* Metastatic disease (M1)\n* Performance status (ECOG) \\> or = 3\n* Current malignancy or history of prior malignancy within past 10 years (with the exception of adequately treated non-melanoma skin cancer and carcinoma in situ of the uterine cervix)\n* Neutrophils \\< 2.000/mm\u00b3 , platelets \\< 100.000/mm\u00b3 , hemoglobin \\< 10 g/dl.\n* Creatinine \\> 1.25 x the upper normal limit\n* GOT and/or GPT and/or bilirubin \\>1.25 x the upper normal limit.\n* Concomitant conditions that, in the investigator's opinion, contraindicate the use of the drugs in the protocol.\n* Congestive heart failure or history of congestive heart failure, unstable angina pectoris, myocardial infarction, clinically significant valvulopathy or uncontrolled arrhythmias\n* Active infection\n* Incapacity or refusal to provide informed consent.\n* Inability to comply with follow up\n* Pregnant or nursing females.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}